Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection Dr. Divya Colin4 May 2025 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has granted approval to...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis Ruchika Sharma18 Feb 2025 3:42 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Biocon Biologics gets Japenese nod for Psoriasis Vulgaris injection Ustekinumab BS Ruchika Sharma7 Jan 2025 1:15 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the...
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Ustekinumab Offers Potential in Protecting Beta-Cells for Adolescents with Type 1 Diabetes, Study Suggests Nidhi Srivastava29 Aug 2024 8:00 PM ISTUK: A multicenter, double-blind, randomized phase 2 trial of Ustekinumab for adolescents with type 1 diabetes was featured in an article in Nature...
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan Ruchika Sharma29 Aug 2024 12:30 PM ISTBangalore: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced today that the...
Sandoz unveils biosimilar Pyzchiva across Europe to treat chronic inflammatory diseases Ruchika Sharma28 July 2024 10:30 AM ISTBasel: Sandoz has announced the launch of Pyzchiva (ustekinumab) across Europe. Pyzchiva, developed and registered by Samsung Bioepis, a ustekinumab...
Sandoz confirms European Commission nod of Pyzchiva Ruchika Sharma23 April 2024 11:54 AM ISTBasel: Sandoz has announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab) developed...
Guselkumab Shows Superior Efficacy Over Ustekinumab for treatment of Psoriatic Arthritis: Study Dr Riya Dave13 March 2024 11:45 PM ISTPsoriatic arthritis is a chronic inflammatory condition that affects joints and skin, often causing pain, swelling, and skin lesions. Biologic...
